Valeant earnings, outlook top

Investor's Business Daily

The Canadian drugmaker said Q3 EPS jumped 74% to $1.15, beating views by 3 cents. Sales rose 47% to $884 mil, in line with views, on successful products like its cold-sore ointment Zovirax and eczema cream Elidel and the acne-wrinkle treatment Retin-A Micro. Valeant (VRX) guided Q4 EPS to $1.30-$1.35, above analyst views of $1.29. The company's full '12 range is now $4.60-$4.65, also above views. Shares fell 0.7% to 56.37.

View Comments (0)